GeneLink Inc. and Prime Succession Inc. Announce DNA Banking Services Throughout Funeral Home System.

MARGATE, N.J. and ERLANGER, Ky.--(BW HealthWire)--Dec. 1, 1998-- GeneLink Inc. (NASDAQ:GNLK) and privately-held Prime Succession Inc. Wednesday announced that Prime Succession has begun offering GeneLink's DNA Banking Services throughout it's funeral home system.

Prime Succession owns and operates 144 funeral homes and 20 cemeteries in 20 states.

GeneLink is a publicly held company with headquarters in Margate, New Jersey. The Company's shares commenced trading recently on the NASDAQ Electronic Bulletin Board under the symbol GNLK.

GeneLink has created a DNA Banking Service that stores DNA before or after an individual dies. This genetic history can help families determine if they are at risk for certain inherited diseases. Humans have over 100,000 genes and there are more than 4,500 diseases that are genetically based.

As researchers continue to identify diseases linked to genes, living family members can use the stored DNA in specific instances to discover if they are at risk for certain diseases. DNA banking shifts the emphasis from diagnosis and treatment to disease prediction and prevention.

GeneLink is currently introducing its service through funeral homes across the country. According to Gary Wright, president of Prime Succession Inc., "We have an obligation to make families aware of their last to chance to participate in this important program which may provide an opportunity to prevent disease in future generations".

GeneLink's patentable DNA Collection Kit involves a simple and noninvasive process for collecting saliva. The DNA is then sent to the University of North Texas Health Science Center in Fort Worth, Texas, for processing and storage. For a fee of $250 the DNA is banked for 25 years.

"It is my belief that every family should request that their funeral director collect the DNA of a deceased family member", said Dr. Stephen L. Putthoff, Chairman of the Department of Pathology of the University of North Texas. It will provide the physicians of future generations with the necessary data to address or prevent inherited diseases.

This release includes certain forward-looking information that is based upon management's beliefs as well as on assumption made by and data currently available to management.

This information which has been, or in the future may be, included in reliance on the "safe harbor" provisions on the Private Securities Litigation Reform Act of 1995, is subject to a number of risks and uncertainties, including but not limited to the factors identified in the Company's documents filed with the Securities and Exchange Commission.

Actual results may differ materially from those anticipated in such forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein may not be realized.